Medicine and Dentistry
Neoplasm
100%
Recurrent Disease
76%
Adjuvant Therapy
66%
Surgery
61%
Pancreas Cancer
57%
Biopsy
49%
Adjuvant Chemotherapy
49%
Conservative Treatment
49%
Heterotopia
49%
Malignant Neoplasm
49%
Gastrointestinal Stromal Tumor
49%
Transplantation
49%
Proteus Syndrome
49%
Renal Pathology
49%
Bevacizumab
49%
Bleeding
49%
Cholangiocarcinoma
49%
Hereditary Hemorrhagic Telangiectasia
49%
Colorectal Cancer
49%
Enteritis
49%
Acinic Cell Carcinoma
49%
Colorectal Polyp
49%
Nephrectomy
49%
Hematopoietic Stem Cell
49%
Polypectomy
49%
Lung
49%
T-Cell Response
49%
Mitosis Rate
44%
Immune Checkpoint Inhibitor
41%
Kidney Injury
37%
Overall Survival
29%
Membranous Glomerulonephritis
24%
Magnetic Resonance Imaging
24%
Hyaline
24%
Complement Component C4d
24%
Glomerulonephritis
24%
Pancreas Adenocarcinoma
22%
Diseases
21%
Epistaxis
18%
Disease
18%
Duodenum
16%
Patient Selection
16%
Infliximab
16%
Kaplan Meier Method
16%
Tumor Immunity
14%
Liver Metastasis
14%
Abdominal Pain
13%
Glomerulopathy
12%
Leukemia
12%
Glomerulus Basement Membrane
12%
Keyphrases
Mitotic Rate
49%
Periampullary Cancer
49%
Adjuvant Therapy
49%
Diagnosis-to-treatment Interval
49%
Malignant Colorectal Polyps
49%
Oncological Outcomes
49%
Adjuvant Chemotherapy
49%
Pancreatic Heterotopia
49%
Gastrointestinal Stromal Tumor
49%
Appendiceal
49%
Small Bowel Hemorrhage
49%
Histological Subtypes
49%
Uncommon Location
49%
Feature Measurement
49%
Risk Assessment
49%
Cobimetinib
49%
Pancreatic Cancer
49%
CASPER
49%
L-asparaginase
49%
Phase I Trial
49%
Lung Recurrence
49%
Ongoing Replication
49%
Asparagine Synthetase
37%
Asparagine
37%
Overall Survival
29%
Tumor
24%
Metastatic Pancreatic Ductal Adenocarcinoma
24%
Pancreatic Ductal Adenocarcinoma
24%
MEK Inhibitor (MEKi)
24%
Tumor Killing
24%
Organotropism
21%
Satellitosis
18%
Danicopan
16%
Lutetium
12%
Squamous Cell Differentiation
12%
Fungal Invasion
12%
Infection-fungal
12%
Kidney Resection
12%
Fibrillary Glomerulonephritis
12%
Rectum
12%
Small Intestine
12%
Stomach
12%
Spindle Cell
12%
Clinical Benefit
12%
Glutamine
12%
Advanced or Metastatic
12%
Tolerability
12%
Starvation
12%
Tumor Cell Resistance
12%
Treatment Strategy
12%